Wyeth, Baxter Recombinant Factor VIII Licenses Subject Of FTC Inquiry
Executive Summary
Wyeth and Baxter have been contacted by the Federal Trade Commission to provide documentation regarding licensing agreements for their recombinant factor VIII hemophilia A products
You may also be interested in...
Wyeth To File Refacto AF Second Quarter; Will Launch End Supply Problems?
Wyeth plans to file its second-generation antihemophilic factor VIII product Refacto AF during the second quarter, Wyeth President-Global Pharmaceuticals Bernard Poussot said during a Jan. 28 analyst call
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials